Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Alzheimer, Donanemab
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in researc
Surrey Alzheimer's drug trial patient shares his experience of donanemab effects
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and content measurement, audience insights and product development. List of Partners (vendors)
NICE rejects Alzheimer’s drug donanemab owing to cost and “significant health risks”
The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the “relatively small benefit” it provides does not outweigh its cost.1 The draft guidelines,
9m
Alzheimer’s trials seeks tens of thousands of volunteers after landmark drug rejected
NICE has said the Alzheimer's disease drug is too expensive to be available on the NHS, but researchers are now hoping to ...
The Pharma Letter
20h
Second Alzheimer’s drug, donanemab, rejected for NHS use
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...
Outsourcing-pharma
20h
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
1d
Second ‘game-changing’ Alzheimer’s drug donanemab gets green light in UK – but WON’T be available on NHS
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
Yahoo
7h
Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
The National Institute for Health and Care Excellence (Nice) confirmed on Wednesday that it would not fund
donanemab
- the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback